Business Context and Reporting Period
Aptevo Therapeutics Inc. filed this Form 8-K on December 12, 2016, to report the entry into a material definitive agreement. The filing concerns a Third Amendment to a License and Co-Development Agreement between Aptevo Research and Development LLC (a subsidiary of Aptevo) and MorphoSys AG regarding the joint development of MOR209/ES414, a targeted immunotherapeutic protein for prostate cancer.
Key Financial Metrics
This filing is a Current Report on Form 8-K and does not contain audited financial statements, revenue, profit, cash flow, or liquidity metrics. The document focuses exclusively on the terms of the amended collaboration agreement.
Material Changes Versus Prior Period
The Third Amendment modifies the cost-sharing structure and termination rights of the existing Collaboration Agreement:
- Cost Allocation Changes:
- Jan 1, 2017 – June 30, 2017: Aptevo bears 75% of development costs; MorphoSys bears 25%.
- July 1, 2017 – Dec 31, 2018: Aptevo bears 49% of development costs; MorphoSys bears 51%.
- Post-Jan 1, 2019: Aptevo bears 36% of development costs; MorphoSys bears 64%.
- Termination Rights: MorphoSys gained the right to terminate the agreement for convenience (i) within one week following the receipt and discussion of certain test results, or (ii) at any time during the last two weeks of June 2017.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or management commentary on future performance. The primary risk disclosed is the amended convenience termination right granted to MorphoSys, which allows them to exit the collaboration based on specific test results or within a defined window in mid-2017. The filing notes that the description of the amendment is qualified by reference to the full text of Exhibit 10.1.
Investor Verification Checklist
- Review Exhibit 10.1 (Third Amendment) for the complete legal text of cost-sharing and termination clauses.
- Verify the impact of the increased cost burden on Aptevo's cash runway for the 2017-2018 period.
- Monitor upcoming test results for MOR209/ES414, as these trigger MorphoSys's new termination rights.
- Confirm the status of the collaboration in subsequent filings to ensure the agreement remains active past the June 2017 termination window.